Estimated delivery in United States, on Wednesday 29 Jan 2025
Product Information
Name:
5'-(N-Cyclopropyl)carboxamidoadenosine
Synonyms:
- (2S,3S,4R)-5-(6-amino-9H-purin-9-yl)-N-cyclopropyl-3,4-dihydroxytetrahydrofuran-2-carboxamide (non-preferred name)
- 1-(6-Amino-9H-purin-9-yl)-N-cyclopropyl-1-deoxy-beta-D-ribofuranuronamide
- 1-(6-Amino-9H-purin-9-yl)-N-cyclopropyl-1-deoxy-β-<span class="text-smallcaps">D</span>-ribofuranuronamide
- 1-(6-Amino-9H-purin-9-yl)-N-cyclopropyl-1-deoxyribofuranuronamide
- 5-(6-amino-9H-purin-9-yl)-N-cyclopropyl-3,4-dihydroxytetrahydrofuran-2-carboxamide (non-preferred name)
- 5′-N-Cyclopropylcarboxamide adenosine
- 5′-N-Cyclopropylcarboxamidoadenosine
- Adenosine 5′-N-cyclopropylcarboxamide
- Adenosine 5′-cyclopropylcarboxamide
- Adenosine-5'-(N-cyclopropyl)carboxamide
- See more synonyms
- N-Cyclopropyl adenosine-5'-carboxamide
- Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-N-cyclopropyl-1-deoxy-
- beta-D-Ribofuranuranamide, 1-(6-amino-9H-purin-9-yl)-N-cyclopropyl-1-deoxy-
- β-<span class="text-smallcaps">D</span>-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-N-cyclopropyl-1-deoxy-
- β-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-N-cyclopropyl-1-deoxy-
- 1-(6-Amino-9H-purin-9-yl)-N-cyclopropyl-1-deoxy-β-D-ribofuranuronamide
Description:
adenosine A2 receptor agonist
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Targetmol
Long term storage:
Notes:
Chemical properties
Molecular weight:
320.3
Formula:
C13H16N6O4
Purity:
98%
Color/Form:
Solid
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TM-T22523 5'-(N-Cyclopropyl)carboxamidoadenosine
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
